Boehringer Ingelheim Limited Archives

Home / Posts tagged Boehringer Ingelheim Limited

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody fragment-based platform Agreement provides potential for up to approx. USD 570 million in total payments including approx. USD 48 million in upfront and near-term payments, plus tiered royalties Ingelheim, Germany and Zurich, Switzerland – November 4, 2025 – Boehringer Ingelheim and CDR-Life, [...]

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

The licensed small molecule program aims to address significant unmet needs for autoimmune diseases. Program adds to Boehringer’s pipeline and its commitment to deliver breakthrough therapies for patients with inflammatory diseases. Ingelheim, Germany, and Tokyo, Japan, [October 30, 2025] – Boehringer Ingelheim and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and COO: Abdul Mullick) today announced that Boehringer Ingelheim has licensed a pre-clinical program from Kyowa Kirin to develop [...]

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the [...]

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with high medical need. Ingelheim, Germany, and Seoul, Korea, 15 October 2025 – Boehringer Ingelheim and AimedBio, [...]

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1 Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF).2,3 Nerandomilast is a new treatment option for adult [...]

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy versus placebo.1 Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity) but [...]

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough Therapy Designation for the first-line treatment of advanced HER2-mutant NSCLC by the Center for Drug Evaluation (CDE) Boehringer [...]

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. (Image from the company HQ) Collaboration strengthens Boehringer’s pipeline in Eye Health. Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an unmet need. Melanocortin receptor agonists offer a promising, differentiated mechanism that targets key [...]

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1 Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell [...]

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2 Often underappreciated and less recognized, negative symptoms impact [...]